Novo Nordisk (ISIN DK0060534915) stock is trading close to recent levels while investors digest a key development dated September 1, 2026: the launch of the company’s oral Wegovy weight-loss pill in Germany, the European Union’s largest pharmaceutical market, alongside robust obesity-driven growth in its latest half-year report
Oral Wegovy launch puts German market in focus
According to a report by Reuters dated September 1, 2026, Germany is the first country in the European Union where Novo Nordisk has launched the Wegovy pill, marking a strategic entry into a major European obesity market
The same report notes that a Novo Nordisk spokesperson expects pharmacy retail prices for the Wegovy pill to be comparable to Wegovy injection pens, with prices in Germany ranging between EUR 170 and EUR 280 per package depending on dosage as of September 1, 2026, aligning with consumer-focused pricing
Coverage by Euronews on September 1, 2026 confirms that Wegovy pills became available in German pharmacies from that date following EU approval in July 2026, with Germany positioned as the first EU member state to offer the pill form of semaglutide for weight loss on prescription
Stock reaction and recent valuation context
On the Danish stock exchange, Novo Nordisk B shares are quoted at around DKK 291.85, down approximately 1.24% as of an intraday snapshot on September 1, 2026, according to market data from Yahoo Finance, which reflects trading on Nasdaq Copenhagen
MarketScreener data for Novo Nordisk shares traded in Europe show an indicative latest closing price of DKK 292.40 and an intraday level near DKK 292.75 on September 1, 2026, implying the stock is trading only slightly below that recent closing price, with a market capitalization around DKK 201 billion stated in the same overview
In the United States, Novo Nordisk’s American depositary shares listed on the New York Stock Exchange most recently closed at USD 47.73 with a daily change of about 0.99% in an August 2026 session, according to a NYSE quote overview on MarketScreener, illustrating that Novo Nordisk stock maintains a substantial international investor base across home and US markets
Valuation metrics compiled by Zacks on September 1, 2026 indicate that Novo Nordisk shares trade at roughly 13.30 times forward earnings compared with an industry average of 18.71, suggesting Novo Nordisk stock is valued at a discount of about 28.9% to its sector on a price-earnings basis at that point
Obesity franchise drives half-year fundamentals
Recent financial context shows how obesity medicines underpin growth. A detailed summary of Novo Nordisk’s 2026 half-year report cited by Chinese financial outlet STCN on September 1, 2026 states that semaglutide-based products remained the company’s revenue backbone, with total sales of the semaglutide series reaching DKK 1,121.93 billion in the first half of 2026, highlighting the scale of obesity and diabetes treatments in the portfolio
The same report notes that the oral Wegovy pill contributed sales of DKK 5,474.0 million (about USD 855 million) in the first half of 2026, with approximately USD 500 million recorded in the second quarter alone, indicating that oral obesity treatments are rapidly becoming a significant revenue contributor within Novo Nordisk’s obesity franchise
STCN further reports that, in the United States market, cumulative prescriptions for Wegovy tablets exceeded 5 million by mid-July 2026, with weekly prescriptions surpassing 265,000, underscoring the demand trajectory in a key market and the potential for similar momentum in newly opened European markets such as Germany
Analyst commentary compiled by Zacks on September 1, 2026 focuses on another pipeline asset, the CagriSema combination therapy, arguing that Novo Nordisk could narrow the competitive gap with rival Lilly in obesity by advancing such next-generation treatments, while investors currently see the stock trading below sector valuation averages despite its strong obesity position
Pipeline and R&D emphasis on obesity and oral biologics
Beyond Wegovy, Novo Nordisk is investing heavily in obesity and related chronic conditions. Healthcare Digital reported on September 1, 2026 that Novo Nordisk’s public research and development pipeline lists 37 programmes across Phase 1, Phase 2, Phase 3 and filed or approval stages, with around 31 of these programmes related to obesity or diabetes, illustrating strategic concentration on metabolic diseases
The same article highlights an agreement announced in 2026 between Novo Nordisk and Vivtex to develop next-generation oral biologic medicines for obesity, diabetes and related conditions, with a potential deal value of up to USD 2.1 billion. Vivtex will license proprietary oral drug-delivery technologies designed to improve absorption of peptides and proteins, supporting Novo Nordisk’s broader push into oral formulations
The STCN summary of Novo Nordisk’s 2026 half-year figures adds that the European Commission has granted marketing authorization for Wegovy tablets containing 25 milligrams of semaglutide once daily as a GLP-1 receptor agonist for weight management in adults with obesity or overweight plus at least one weight-related comorbidity across all EU member states, positioning the therapy as the first tablet-form GLP-1 agent approved EU-wide for weight management
This regulatory backdrop, combined with the German launch, signals that oral semaglutide-based obesity treatments are now a central growth pillar alongside injectable formulations, expanding Novo Nordisk’s reach into patient segments that prefer tablets over injections
Go deeper
More on Novo Nordisk stock and semaglutide demand
For investors who want to follow Novo Nordisk stock and the company’s expanding Wegovy and semaglutide franchise, the following re
More articles on DK0060534915Investor Relations
Wegovy as a flagship obesity product
Wegovy, based on semaglutide, is Novo Nordisk’s flagship obesity therapy and now available both as injectable pens and as daily tablets. An Ad-Hoc News product overview dated September 1, 2026 reports that Wegovy pens are priced between EUR 171.96 and EUR 301.97 in Europe at that time, depending on dosage, illustrating the premium pricing of injectable weight-loss treatments relative to many traditional medicines
With the German launch of Wegovy tablets at similar price points and reimbursement structures still emerging across markets, Wegovy’s performance is likely to be central to Novo Nordisk’s obesity revenue trajectory in the coming quarters, particularly as patient access frameworks are clarified in individual EU member states
Stock level and investor perspective
As of September 1, 2026, Novo Nordisk stock on Nasdaq Copenhagen, quoted through the NOVO-B.CO ticker, trades around DKK 291.85, a modest intraday decline of about 1.24% compared with the previous trading level while recent European quote snapshots place the latest closing price at DKK 292.40 and an indicative intraday level close to DKK 292.75 on the same date
Novo Nordisk stock key data
- Company: Novo Nordisk A/S
- ISIN: DK0060534915
- Ticker: NOVO-B.CO
- Trading venue: Nasdaq Copenhagen
- Price (as of September 1, 2026): 291.85 DKK
- Market capitalization: 201,000,000,000 DKK (as of September 1, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: OMX Copenhagen 25
Follow Novo Nordisk stock on social platforms
YouTubeXTikTokInstagram
Disclaimer…
en | DK0060534915 | NOVO NORDISK | boerse | 70039087 | bgmi
